A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease
收藏DataCite Commons2025-06-25 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00011445/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active Crohn's disease (CD).
提供机构：
Vivli
创建时间：
2025-06-03
